Categorynews

Allegro Ophthalmics to Present the Results of Its ALG-1007 Ex-U.S. Trial for Dry Eye Disease at the 2019 ASCRS•ASOA Annual Meeting

April 30, 2019 Off By BusinessWire

ALG-1007 Marks Allegro’s Second Exploratory Anti-Integrin Drug
Candidate—Now, for the Potential Treatment of Dry Eye Disease

SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ASCRS?src=hash" target="_blank"gt;#ASCRSlt;/agt;–Following last week’s news
that the company is expanding its pipeline into dry eye and has created
a new Cornea Scientific Advisory Board (Cornea SAB), Allegro
Ophthalmics, LLC, a privately held biopharmaceutical company focused
on the development of novel anti-integrin therapies for the treatment of
ocular diseases, today announced that the results of its ALG-1007
ex-U.S. proof-of-concept clinical trial for the treatment of dry eye
disease (DED) will be presented during the 2019 American Society of
Cataract and Refractive Surgery and American Society of Ophthalmic
Administrators (ASCRS•ASOA) Annual Meeting being held May 3-7 in San
Diego, CA.

On Thursday, May 2, Allegro’s President and CEO Vicken Karageozian,
M.D., will provide an overview on the company’s vision moving
forward into other ocular indications at the Ophthalmology Innovation
Summit (OIS). Then on Monday, May 6, Eric D. Donnenfeld, M.D.,
will present full study results of the ALG-1007 ex-U.S. proof-of-concept
clinical trial for DED at ASCRS•ASOA.

The expansion into front-of-the-eye indications bolsters Allegro’s
existing anti-integrin portfolio, which includes risuteganib
(Luminate®), currently being developed for diabetic macular edema (DME)
and intermediate dry age-related macular degeneration (intermediate dry
AMD). Pre-clinical and clinical findings of risuteganib convinced the
company that it could develop a new anti-integrin compound to treat DED.

“Allegro is excited to share, for the first time, our ex-U.S.
proof-of-concept data with the clinical community at ASCRS and OIS,”
said Dr. Karageozian. “Allegro is continuously exploring new ways to
apply our anti-integrin portfolio to help improve patients’ vision, and
ALG-1007 represents our first exploratory drug for the potential
treatment of dry eye, a disease that adversely affects millions of
Americans.”

The corporate and scientific presentations are scheduled as follows:

Thursday, May 2: 9:45-9:51 AM
Ophthalmology Innovation Summit,
Hilton San Diego Bayfront
Addressing the Unmet Need of Ocular
Diseases with a Novel Anti-Integrin Portfolio.
Vicken
Karageozian, M.D.
Monday, May 6: 1:45-1:50 AM
San Diego
Convention Center, Room 1B
A Pilot Study to Evaluate the
Safety and Exploratory Efficacy of ALG-1007 Topical Ophthalmic Solution
for the Treatment of Dry Eye Disease. Eric D. Donnenfeld, M.D.

All educational content of the ASCRS•ASOA Annual Meeting is planned
by its program committee, and ASCRS•ASOA does not endorse, promote,
approve, or recommend the use of any products, devices, or services.

About Allegro Ophthalmics, LLC
Allegro
Ophthalmics, LLC is a privately held biopharmaceutical company
focused on the development of novel anti-integrin therapies for the
treatment of ocular diseases. Pre-clinical data suggest that risuteganib
(Luminate®), Allegro’s lead investigational anti-integrin compound in
retina, simultaneously acts on the angiogenic, inflammatory and
mitochondrial metabolic pathways implicated in diseases such as DME and
intermediate dry AMD. Risuteganib successfully completed two Phase 2 DME
studies and is currently being evaluated in a U.S. Phase 2 intermediate
dry AMD study. Expanding its anti-integrin portfolio, Allegro has
developed ALG-1007, an anti-integrin drug candidate for topical use in
DED. ALG-1007 has successfully completed an ex-U.S. proof-of-concept
study in humans, and is currently being evaluated in a larger ex-U.S.
Phase 2 study. For more information, visit www.allegroeye.com.